WallStSmart

Doximity Inc (DOCS)vsHealthEquity Inc (HQY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

HealthEquity Inc generates 106% more annual revenue ($1.31B vs $637.78M). DOCS leads profitability with a 37.5% profit margin vs 16.4%. DOCS appears more attractively valued with a PEG of 0.69. HQY earns a higher WallStSmart Score of 66/100 (B-).

DOCS

Strong Buy

66

out of 100

Grade: B-

Growth: 5.3Profit: 9.0Value: 8.0Quality: 8.3
Piotroski: 6/9Altman Z: 5.72

HQY

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 7.0Value: 6.7Quality: 6.5
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DOCSUndervalued (+44.4%)

Margin of Safety

+44.4%

Fair Value

$46.71

Current Price

$25.98

$20.73 discount

UndervaluedFair: $46.71Overvalued
HQYUndervalued (+54.2%)

Margin of Safety

+54.2%

Fair Value

$168.11

Current Price

$84.84

$83.27 discount

UndervaluedFair: $168.11Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DOCS5 strengths · Avg: 9.4/10
Profit MarginProfitability
37.5%10/10

Keeps 38 of every $100 in revenue as profit

Operating MarginProfitability
38.9%10/10

Strong operational efficiency at 38.9%

Altman Z-ScoreHealth
5.7210/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
23.8%9/10

Every $100 of equity generates 24 in profit

PEG RatioValuation
0.698/10

Growing faster than its price suggests

HQY2 strengths · Avg: 9.0/10
EPS GrowthGrowth
92.4%10/10

Earnings expanding 92.4% YoY

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Areas to Watch

DOCS1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-16.2%2/10

Earnings declined 16.2%

HQY1 concerns · Avg: 4.0/10
P/E RatioValuation
34.1x4/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : DOCS

The strongest argument for DOCS centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 37.5% and operating margin at 38.9%. PEG of 0.69 suggests the stock is reasonably priced for its growth.

Bull Case : HQY

The strongest argument for HQY centers on EPS Growth, Operating Margin. Profitability is solid with margins at 16.4% and operating margin at 21.6%. PEG of 1.19 suggests the stock is reasonably priced for its growth.

Bear Case : DOCS

The primary concerns for DOCS are EPS Growth.

Bear Case : HQY

The primary concerns for HQY are P/E Ratio.

Key Dynamics to Monitor

DOCS carries more volatility with a beta of 1.35 — expect wider price swings.

DOCS is growing revenue faster at 9.8% — sustainability is the question.

HQY generates stronger free cash flow (102M), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DOCS scores higher overall (66/100 vs 66/100), backed by strong 37.5% margins. HQY offers better value entry with a 54.2% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Doximity Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Doximity, Inc. (Ticker: DOCS) is a U.S. healthcare technology company that operates a digital platform tailored for medical professionals. The company’s cloud-based network provides secure communication and collaboration tools, telemedicine services, clinical workflow solutions, and access to medical news, research, and career-management features for physicians, nurse practitioners, physician assistants, and other clinicians. Headquartered in San Francisco, California, Doximity’s Class A common stock trades on the New York Stock Exchange under the ticker DOCS.

HealthEquity Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

HealthEquity, Inc. provides technology-enabled service platforms to consumers and employers in the United States. The company is headquartered in Draper, Utah.

Want to dig deeper into these stocks?